← FDA DRUG APPROVALS

FDA ANDA · ANDA201529

METHOTREXATE

Sponsor: EUGIA PHARMA SPECLTS

APPLICATION
ANDA201529
TYPE
ANDA
ORIGINAL APPROVAL
2012-03-29
LATEST ACTION
2021-07-19
ROUTE
INTRAMUSCULAR, INTRATHECAL, INTRAVENOUS, SUBCUTANEOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

METHOTREXATE SODIUM PRESERVATIVE FREEPrescription
METHOTREXATE SODIUM EQ 200MG BASE/8ML (EQ 25MG BASE/ML) · INJECTABLE · INJECTION
METHOTREXATE SODIUM PRESERVATIVE FREEPrescription
METHOTREXATE SODIUM EQ 50MG BASE/2ML (EQ 25MG BASE/ML) · INJECTABLE · INJECTION
METHOTREXATE SODIUM PRESERVATIVE FREEPrescription
METHOTREXATE SODIUM EQ 250MG BASE/10ML (EQ 25MG BASE/ML) · INJECTABLE · INJECTION
METHOTREXATE SODIUM PRESERVATIVE FREEPrescription
METHOTREXATE SODIUM EQ 100MG BASE/4ML (EQ 25MG BASE/ML) · INJECTABLE · INJECTION

Approval history

2021-07-19Labeling · Supplement 7 · standardAP
2021-07-19Labeling · Supplement 10 · standardAP
2015-10-05Labeling · Supplement 4 · standardAP
2015-10-05Labeling · Supplement 3 · standardAP
2012-03-29Not Applicable · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →